Common Findings on Screening Tests and Suggested Management

This summary organizes the key recommendations from the Common Findings on Screening Tests and Suggested Management article.
It is designed to support the Migration Humanitarian Health Collective’s clinician‑facing platform.

Abnormal Complete Blood Count (CBC)

Iron‑deficiency anemia

• Chronic nutritional deficiencies and hookworm infection are common causes in refugees.

• Treatment involves oral ferrous sulfate 300 mg three times daily for 3 months. If malabsorption is suspected, intravenous iron can be used.

• Repeat CBC after therapy; if microcytosis persists (> 3 months), evaluate for thalassemia or hemoglobinopathy.

Neutropenia

• Benign ethnic neutropenia is common in immigrants from Africa, the Middle East and the Caribbean.

• Work‑up should include a repeat CBC with differential, smear review for spherocytes, target cells or nucleated red cells, and evaluation for malaria, HIV and hepatitis B/C.

• If neutrophils remain < 0.8 × 10⁹ cells/L or if symptoms of infection are present, refer to hematology and investigate for nutritional deficiencies, autoimmune disease or bone marrow suppression.

Red‑blood‑cell morphology changes

• Target cells suggest liver disease or thalassemia; spherocytes suggest hereditary spherocytosis or autoimmune hemolysis; schistocytes indicate microangiopathy.

• Evaluate abnormal morphology with hemolysis labs (LDH, bilirubin, haptoglobin), liver enzymes and coagulation profile.

Eosinophilia

• Defined as > 0.5 × 10⁹ cells/L on the CBC. Eosinophilia in refugees is usually due to helminth infection.

• Empiric therapy includes a 3‑day course of albendazole (400 mg orally once daily) plus ivermectin (200 μg/kg/day for 2 days). If there is risk of schistosomiasis (endemic exposures or positive serology), add praziquantel 40 mg/kg in two divided doses.

• Persistent or severe eosinophilia warrants referral to infectious disease and further work‑up (stool for parasites, serology for Strongyloides and Schistosoma, chest imaging).

Abnormal Newborn/Hemoglobinopathy Screening

Alpha‑thalassemia

• Trait (one or two gene deletions) causes microcytosis and mild anemia; patients are usually asymptomatic. No treatment is needed, but carriers should avoid unnecessary iron therapy. They should discuss carrier status with partners to assess fetal risk.

• Hemoglobin H disease (three gene deletions) can cause moderate anemia and should be referred to hematology.

Beta‑thalassemia

• Minor (heterozygous β‑thalassemia) produces microcytosis and mild anemia; no treatment is required, but families should receive genetic counselling.

• Intermedia produces moderate anemia; patients may require occasional transfusion and iron chelation.

• Major (β⁰/β⁰) causes severe anemia that requires regular transfusions; refer urgently to hematology and offer genetic counselling.

Sickle‑cell disease

• Trait (HbAS): individuals are generally healthy but should avoid extreme exertion, dehydration and high altitude.

• Disease (HbSS or variants): newborns should be referred immediately to a pediatric hemoglobinopathy clinic. Prophylactic penicillin is given until age five, and children require vaccination against encapsulated organisms.

G6PD deficiency

• Many refugees originate from regions where glucose‑6‑phosphate dehydrogenase (G6PD) deficiency is prevalent.

• Diagnostic confirmation requires quantitative G6PD assay; screening tests may be falsely negative when patients are not hemolyzing.

• Patients should avoid oxidative triggers such as fava beans, mothballs, and drugs like dapsone, sulfonamides and primaquine.

• Acute hemolytic episodes are managed supportively; refer to hematology if persistent hemolysis.

Viral Serology Findings

Hepatitis B serology

Interpretation of hepatitis B markers and suggested management:

Serologic pattern

Interpretation

Management

HBsAg‑, anti‑HBs‑, anti‑HBc‑

Susceptible

Begin three‑dose HBV vaccine series at 0, 1 and 6 months; test anti‑HBs after vaccination.

HBsAg‑, anti‑HBs+, anti‑HBc+

Immune due to natural infection

No treatment; counsel regarding lifetime immunity.

HBsAg‑, anti‑HBs+, anti‑HBc‑

Immune due to vaccination

No action required.

HBsAg‑, anti‑HBs‑, anti‑HBc+

Unclear (resolved infection vs false positive)

Check HBV DNA and repeat serology in 1 month; if DNA positive, treat as chronic infection.

HBsAg+, IgM anti‑HBc+

Acute infection

Refer to infectious disease; monitor liver enzymes; advise household contacts to be vaccinated.

HBsAg+ ≥ 6 months

Chronic infection

Refer to hepatology for evaluation; order HBV DNA, ALT and ultrasound; vaccinate against hepatitis A.

Hepatitis C serology

• An indeterminate or positive anti‑HCV screen should be followed with HCV RNA testing to distinguish active from cleared infection.

• Patients with positive RNA should be referred to hepatology or infectious diseases for evaluation and treatment with direct‑acting antivirals.

• Those with cleared infection (RNA –) need counselling on prevention and periodic screening if risk factors persist.

HIV serology

• A positive HIV screening test must be confirmed using a second generation immunoassay.

• Newly diagnosed individuals require immediate referral to an HIV specialist for evaluation, baseline viral load and CD4 count, and initiation of antiretroviral therapy.

• Screen for co‑infections (hepatitis B/C, syphilis, TB) and provide counselling on transmission and safe practices.

Varicella serology

• Refugees lacking varicella IgG should receive the 2‑dose varicella vaccine (given 4–6 weeks apart), unless contraindicated.

• Pregnant or immunocompromised patients with exposure may require varicella‑zoster immunoglobulin and post‑exposure prophylaxis; consult infectious disease.

Positive Parasitic Serologies

Strongyloides

• A positive Strongyloides serology warrants treatment due to risk of hyperinfection during immunosuppression.

• Treat with ivermectin 200 µg/kg/day for two days.

• Evaluate for eosinophilia and consider retreatment or extended therapy if immunocompromised. Repeat serology in 6–12 months to document cure.

Schistosoma

• A positive Schistosoma serology requires treatment even if asymptomatic.

• Administer praziquantel 40 mg/kg in two divided doses on the same day.

• Post‑treatment stool and urine microscopy are not necessary; serology may remain positive for years. Repeat treatment if exposure continues.

Positive Latent Tuberculosis (TB) Screening

• Patients with a positive tuberculin skin test (TST) or interferon‑γ release assay (IGRA) need a chest X‑ray to rule out active disease.

• Symptomatic patients or those with abnormal chest X‑ray require isolation and urgent evaluation for active TB; refer to TB services.

• If active disease is excluded, refer to TB Services for latent TB therapy. The preferred regimen is 3 months of self‑administered isoniazid and rifampin; an alternative is 4 months of rifampin alone for patients at higher risk of hepatotoxicity.

• TB Services dispense medication monthly and provide follow‑up; family physicians should monitor adherence and conduct monthly liver function tests where indicated.

• Educate patients on potential side effects (e.g., hepatitis symptoms with isoniazid, orange discoloration of fluids with rifampin).

Positive Syphilis Serology

• In Alberta, a positive syphilis enzyme immunoassay (EIA) is automatically followed by a Treponema pallidum particle agglutination assay (TPPA) and rapid plasma reagin (RPR).

• A positive TPPA suggests current or past infection. Clinicians should discuss all positive results with Alberta Health Services (AHS) STI Centralized Services to obtain guidance on staging and treatment.

• An isolated EIA+ / TPPA– / RPR– result is usually a false positive; repeat serology in 2–3 weeks to exclude early infection.

• Perform a thorough history and physical examination, including genital, skin, neurological and cardiac assessments. Screen for other STIs and obtain sexual history.

• Early syphilis (primary, secondary or early latent) is treated with a single intramuscular dose of benzathine penicillin G 2.4 MU, whereas late latent syphilis requires benzathine penicillin G 2.4 MU weekly for three weeks. Always discuss treatment with STI Centralized Services.

• Refer to provincial STI treatment guidelines for detailed management.

Implementation Guidance

• Create separate resource pages on the platform for each top‑level category, following Gabe Fabreau’s standardized template (epidemiology, clinical presentation, investigations, management/treatment, contextual considerations, references and update date).

• Use the summaries above as initial content; hyperlink to authoritative references (e.g., WHO, CDC, provincial guidelines) and add interactive tools such as downloadable patient handouts or decision algorithms.

• Include feedback mechanisms (e.g., “Was this page useful?”) and ensure each page notes the last update date and reviewer.